ArticleScientific reports2025
Dietary carotenoids and risk of dyslipidemia among adult participants of Tehran Lipid and Glucose Study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, particular attention has focused on the potential cardio-protective properties of dietary carotenoids. Here we aimed to evaluate the association between dietary intakes of carotenoids (α-carotene, β-carotene, lycopene, lutein, and β-cryptoxanthin) and risk of dyslipidemia (elevated levels of total cholesterol (HTC), low-density lipoprotein cholesterol (HLDL), triglycerides (HTG), or reduced levels of high-density lipoprotein cholesterol (LHDL)) among adult participants of Tehran Lipid and Glucose Study (TLGS). The present prospective cohort study was conducted in four separate analyses, HTG analysis with 1305 healthy adults, HLDL analysis with 1326 healthy adults, HTC analysis with 1311 healthy adults, and LHDL analysis with 711 healthy adults from the participants of the third phase (2006-2008) of the TLGS. Dietary intake of carotenoids was estimated using a validated 168-items semi-quantitative food frequency questionnaire, at baseline. Adjusted Hazard Ratios (HRs) and 95% confidence intervals (CIs) of HTC, HTG, LHDL, and HLDL were calculated in tertile categories of dietary carotenoids. Participants in the second tertile of β-cryptoxanthin intake, had a 24% lower risk of HLDL (HR = 0.76, 95%CI: 0.60-0.96), and an 18% lower risk of HTC (HR = 0.82, 95%CI: 0.66-0.98), compared to the participants in the first tertile. Also, participants in the second tertile of lycopene intake, compared to those in the first tertile had a 23% lower risk of HTG (HR = 0.77, 95%CI: 0.63-0.97). There was no significant association between other dietary carotenoids and dyslipidemia. The results indicated beneficial effects of dietary β-cryptoxanthin and lycopene for lipid profile. However, more research is needed to clarify the specific mechanisms and to determine optimal nutritional sources and amounts of carotenoids for cardiovascular benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.